Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Post author: Post published:April 20, 2026 Post category: Continue ReadingGenetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Post author: Post published:April 20, 2026 Post category: Continue ReadingGene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors Post author: Post published:April 20, 2026 Post category: Continue ReadingA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
GCC19CART for Patients With Metastatic Colorectal Cancer Post author: Post published:April 20, 2026 Post category: Continue ReadingGCC19CART for Patients With Metastatic Colorectal Cancer
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Post author: Post published:April 20, 2026 Post category: Continue ReadingLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer Post author: Post published:March 25, 2026 Post category: Continue ReadingCCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma Post author: Post published:March 25, 2026 Post category: Continue ReadingPembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma Post author: Post published:March 17, 2026 Post category: Continue ReadingExpanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel Post author: Post published:March 17, 2026 Post category: Continue ReadingExpanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Post author: Post published:March 17, 2026 Post category: Continue ReadingA Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
